Clinical trials: High-dose Chemotherapy
Neuroblastoma
Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma
The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCR in children with high-risk neuroblastoma. In the present study, a single arm trial of tandem HDCT/ASCR will be carried out.
- Trial name
- NCT00793845
- Testing
- Cyclophosphamide, Etoposide, Carboplatin
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Metastatic Melanoma, Skin Cancer
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Background: Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can…
- Trial name
- NCT01495572
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002630
- Testing
- filgrastim, cyclophosphamide, melphalan
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01045928
- Testing
- lenalidomide, rituximab, polymerase chain reaction
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Squamous Cell Carcinoma, Head and Neck Cancer
MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck
Rationale for Study Oral mucositis is a major complication arising from contemporary chemoradiation treatment of patients with head and neck cancer. No effective therapy exists to prevent this complication in this population.
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer, Resected Head and Neck Cancer, Mucositis
- Trial name
- NCT00427102
- Testing
- Oral MRX-1024, Standard Fractionation Radiation Therapy, High-Dose Cisplatin Chemotherapy
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
The purpose of this study is to evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units meeting a predetermined total minimum cell dose of 2.0 x 10 to the seventh total nucleated cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma
- Trial name
- NCT00328237
- Testing
- Cord Blood Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Multiple Myeloma
Treatment Optimization in Patients With Untreated Multiple Myeloma
This is a multicenter, randomized, blinded, 2-arm phase IIb trial that will compare the efficacy and safety of Lenalidomide maintenance after Bortezomib/Melphalan/Prednison (VMP) induction to VMP without maintenance (Placebo).
- Trial name
- GERMAIN (NCT02145598)
- Testing
- Lenalidomide
- Where
- 19 sites in Germany
- Volunteers
- 85 people
- Sponsor
- Dr. med. Lars-Olof Muegge
Breast Cancer
High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003392
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, Myeloma
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
The purpose of this study is to evaluate the efficacy and tolerance of a single administration of Pegfilgrastim in patients with lymphoma or myeloma receiving high-dose chemotherapy and autologous peripheral stem cell support…
- Trial name
- PALM (NCT00794261)
- Testing
- Injection of Pegfilgrastim, Injection of Filgrastim
- Where
- 11 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Leon Berard
Brain Tumors, Central Nervous System Tumors
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003573
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 106 sites in United States, Canada and 3 more
- Volunteers
- 53 people
- Sponsor
- Children's Oncology Group
Central Nervous System Lymphoma
High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma
The involvement of the central nervous system (CNS) by non-Hodgkin lymphoma (NHL) has carried a poor prognosis. For both of primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL)…
- Trial name
- NCT06625359
- Testing
- Thiotepa in conditioning before transplantation
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Adenocarcinoma of Breast
Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer
This study was a transnational pooled analysis of biological material from patients with resected high risk breast cancer who had received adjuvant chemotherapy with epirubicin and cyclophosphamide followed by weekly docetaxel or…
- Trial name
- NCT04829890
- Volunteers
- 89 people
- Sponsor
- Hellenic Cooperative Oncology Group
Esophageal Cancer
Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
Definitive chemoradiation is the standard treatment for locally advanced esophageal cancer. NCCN (National Comprehensive Cancer Network) recommends radiation dose of 50-50.4 Gy as the definitive radiation dose for esophageal…
- Trial name
- NCT02850991
- Testing
- High-dose, Standard-dose
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Peking University Cancer Hospital & Institute
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation and immunotherapy may allow the…
- Trial name
- NCT00046852
- Testing
- filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes
- Where
- 2 sites in United States
- Sponsor
- University of Maryland, Baltimore
Non-Hodgkin Lymphoma, Hodgkin Disease
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts.
- Conditions
- Non-Hodgkin Lymphoma, Hodgkin Disease, Thrombocytopenia
- Trial name
- NCT00039910
- Testing
- (PN-152,243)/ PN-196,444
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 240 people
- Sponsor
- Pfizer
Lymphoma
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00003815
- Testing
- bleomycin sulfate, carmustine, cyclophosphamide
- Where
- United Kingdom
- Sponsor
- Scotland and Newcastle Lymphoma Group
Lymphoma
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Giving chemotherapy drugs, such as melphalan, before an autologous stem cell transplant helps stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392691
- Testing
- ibritumomab tiuxetan, rituximab, melphalan
- Where
- 10 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
This research focuses on women with breast cancer whose disease has not significantly progressed, but who have 5 or more lymph nodes involved.
- Trial name
- NCT00378638
- Testing
- bevacizumab combined with dose dense chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Chap, Linnea I., M.D.
Acute Myeloid Leukemia
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
The purpose of this study is: 1. To compare priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) during induction and consolidation courses versus no priming. 2.
- Trial name
- NCT00880243
- Testing
- GM-CSF
- Volunteers
- 473 people
- Sponsor
- Acute Leukemia French Association
Gastric Cancer
High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving higher doses may kill more tumor cells.
- Trial name
- NCT00002722
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Volunteers
- 135 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC